Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Läkemedel i klinisk praxis: Hur får vi bättre kunskap? - Nationell samordning behövs för läkemedelsuppföljning.

Feltelius N.

Lakartidningen. 2019 Apr 2;116. pii: FLMZ. Swedish. No abstract available.

PMID:
31192387
Free Article
2.

Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.

Granath F, Gedeborg R, Smedje H, Feltelius N.

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1045-1053. doi: 10.1002/pds.4788. Epub 2019 May 6.

PMID:
31062443
3.

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, Dejaco C, Dixon WG, Feltelius N, Finckh A, Gilbert K, Mackie SL, Mahr A, Matteson EL, Neill L, Salvarani C, Schmidt WA, Strangfeld A, van Vollenhoven RF, Buttgereit F.

Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21.

PMID:
30898837
4.

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.

Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J; ARTIS Study Group .

Rheumatology (Oxford). 2019 Jan 21. doi: 10.1093/rheumatology/key433. [Epub ahead of print]

PMID:
30668875
5.

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, Weiland O.

Eur J Clin Pharmacol. 2018 Jul;74(7):971-978. doi: 10.1007/s00228-018-2456-y. Epub 2018 Apr 9.

6.

The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction.

Bomfim IL, Lamb F, Fink K, Szakács A, Silveira A, Franzén L, Azhary V, Maeurer M, Feltelius N, Darin N, Hallböök T, Arnheim-Dahlström L, Kockum I, Olsson T.

Genes Immun. 2017 Mar;18(2):75-81. doi: 10.1038/gene.2017.1. Epub 2017 Mar 23.

PMID:
28332559
7.

Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective.

Feltelius N, Gedeborg R, Holm L, Zethelius B.

Ups J Med Sci. 2017 Jun;122(2):136-147. doi: 10.1080/03009734.2017.1285837. Epub 2017 Mar 3.

8.

Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study.

Gedeborg R, Svennblad B, Holm L, Sjögren H, Bardage C, Personne M, Sjöberg G, Feltelius N, Zethelius B.

Pharmacoepidemiol Drug Saf. 2017 May;26(5):518-527. doi: 10.1002/pds.4166. Epub 2017 Jan 13.

PMID:
28083980
9.

Response to letter from Lars Andersson.

Persson I, Feltelius N.

J Intern Med. 2017 Jan;281(1):96-98. doi: 10.1111/joim.12573. No abstract available.

10.

Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N.

J Intern Med. 2017 Jan;281(1):102-104. doi: 10.1111/joim.12581. No abstract available.

11.

Risk for Congenital Malformation With H1N1 Influenza Vaccine: A Cohort Study With Sibling Analysis.

Ludvigsson JF, Ström P, Lundholm C, Cnattingius S, Ekbom A, Örtqvist Å, Feltelius N, Granath F, Stephansson O.

Ann Intern Med. 2016 Dec 20;165(12):848-855. doi: 10.7326/M16-0139. Epub 2016 Sep 20.

PMID:
27654505
12.

[New diagnostics and treatments in gout].

Kapetanovic M, Feltelius N.

Lakartidningen. 2016 Jul 15;113. pii: D4AM. Swedish. No abstract available.

13.

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.

Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J; ARTIS Study Group, For the DANBIO Study Group.

Ann Rheum Dis. 2017 Jan;76(1):105-111. doi: 10.1136/annrheumdis-2016-209270. Epub 2016 May 4.

PMID:
27147709
14.

Authors' reply to Makiyama and colleagues.

Ludvigsson JF, Ström P, Lundholm C, Cnattingius S, Ekbom A, Örtqvist Å, Feltelius N, Granath F, Stephansson O.

BMJ. 2016 Feb 16;352:i776. doi: 10.1136/bmj.i776. No abstract available.

PMID:
26883508
15.

Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design.

Ludvigsson JF, Ström P, Lundholm C, Cnattingius S, Ekbom A, Örtqvist Å, Feltelius N, Granath F, Stephansson O.

BMJ. 2015 Nov 16;351:h5585. doi: 10.1136/bmj.h5585.

16.

A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.

Feltelius N, Persson I, Ahlqvist-Rastad J, Andersson M, Arnheim-Dahlström L, Bergman P, Granath F, Adori C, Hökfelt T, Kühlmann-Berenzon S, Liljeström P, Maeurer M, Olsson T, Örtqvist Å, Partinen M, Salmonson T, Zethelius B.

J Intern Med. 2015 Oct;278(4):335-53. doi: 10.1111/joim.12391. Epub 2015 Jun 30. Review.

17.

[Narcolepsy--rare disease that has received increased attention. Pandemrix vaccination caused a higher incidence among children and adolescents].

Hallböök T, Azakacs A, Bialek F, Feltelius N, Landtblom AM, Malmgren K.

Lakartidningen. 2014 Oct 8-14;111(41):1770-3. Review. Swedish. No abstract available.

18.

No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment.

Arkema EV, Feltelius N, Olsson T, Askling J; ARTIS study group.

Ann Rheum Dis. 2014 Nov;73(11):2061-2. doi: 10.1136/annrheumdis-2014-205622. Epub 2014 Aug 5. No abstract available.

PMID:
25096786
19.

Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.

Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J.

Arthritis Rheumatol. 2014 May;66(5):1282-90. doi: 10.1002/art.38339.

20.

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Jun;74(6):1212-7. doi: 10.1136/annrheumdis-2013-204960. Epub 2014 Mar 7.

PMID:
24608401
21.

Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N.

J Intern Med. 2014 Feb;275(2):172-90. doi: 10.1111/joim.12150. Epub 2013 Nov 10. Erratum in: J Intern Med. 2017 Jan;281(1):102-104.

22.

Medical registries represent vital patient interests and should not be dismantled by stricter regulation.

Hansson MG, Simonsson B, Feltelius N, Forsberg JS, Hasford J.

Cancer Epidemiol. 2012 Dec;36(6):575-8. doi: 10.1016/j.canep.2012.06.009. Epub 2012 Jul 15.

PMID:
22796267
23.

Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases.

Hansson MG, Gattorno M, Forsberg JS, Feltelius N, Martini A, Ruperto N.

Arch Dis Child. 2012 Jun;97(6):561-3. doi: 10.1136/archdischild-2011-301175. Epub 2012 Feb 22. No abstract available.

PMID:
22362719
24.

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.

Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12.

PMID:
21228027
25.

Ten years with biologics: to whom do data on effectiveness and safety apply?

Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J.

Rheumatology (Oxford). 2011 Jan;50(1):204-13. doi: 10.1093/rheumatology/keq326. Epub 2010 Nov 16.

PMID:
21084326
26.

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register.

Neovius M, Simard J, Sundström A, Jacobsson L, Geborek P, Saxne T, Feltelius N, Klareskog L, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2011 Mar;70(3):516-9. doi: 10.1136/ard.2010.130914. Epub 2010 Nov 15.

PMID:
21081525
27.

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L; ARTIS Study Group.

Scand J Rheumatol. 2011 Jan;40(1):8-15. doi: 10.3109/03009742.2010.493895. Epub 2010 Oct 18.

PMID:
20955087
28.

Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.

Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J.

Arthritis Rheum. 2010 May;62(5):1252-8. doi: 10.1002/art.27402.

29.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

30.

Patients' understanding of the concepts of health and quality of life.

Fagerlind H, Ring L, Brülde B, Feltelius N, Lindblad AK.

Patient Educ Couns. 2010 Jan;78(1):104-10. doi: 10.1016/j.pec.2009.05.016. Epub 2009 Jun 27.

PMID:
19560893
31.

Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.

Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, Askling J, Baecklund E.

Ann Rheum Dis. 2010 Apr;69(4):654-9. doi: 10.1136/ard.2008.096925. Epub 2009 May 12.

PMID:
19439429
32.

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N.

Ann Rheum Dis. 2009 May;68(5):648-53. doi: 10.1136/ard.2007.085852. Epub 2008 May 8.

PMID:
18467516
33.

Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis.

Baecklund E, Natkunam Y, Backlin C, Iliadou A, Askling J, Ekbom A, Feltelius N, Klareskog L, Enblad G, Lossos IS, Levy R, Sundström C, Rosenquist R.

Br J Haematol. 2008 Apr;141(1):69-72. doi: 10.1111/j.1365-2141.2008.07011.x.

PMID:
18324968
34.

Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency.

Lindfors A, Feltelius N, Lundkvist J.

Int J Technol Assess Health Care. 2007 Summer;23(3):392-6. Review.

PMID:
17579944
35.

[The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].

Sjölin-Forsberg G, Lindeskog B, Lundqvist KM, Feltelius N, Alvan G.

Lakartidningen. 2007 Apr 18-24;104(16):1226-9. Swedish. No abstract available.

PMID:
17536352
36.

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L.

Ann Rheum Dis. 2007 Oct;66(10):1339-44. Epub 2007 Jan 29. Erratum in: Ann Rheum Dis. 2007 Nov;66(11):1548.

37.

Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.

Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundström C, Klareskog L, Askling J, Rosenquist R.

Arthritis Rheum. 2006 Dec;54(12):3774-81.

38.

Sulphasalazine inhibits human antigen-specific immune responses in vivo.

Trollmo C, Gudmundsson S, Feltelius N, Rogberg S, Smedegård G, Klareskog L.

Ann Rheum Dis. 2007 Apr;66(4):481-5. Epub 2006 Sep 19.

39.

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L.

Arthritis Rheum. 2006 Mar;54(3):692-701.

40.

Swedish registers to examine drug safety and clinical issues in RA.

Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S, Klareskog L.

Ann Rheum Dis. 2006 Jun;65(6):707-12. Epub 2006 Jan 13. Review.

41.

Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.

Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N.

Ann Rheum Dis. 2006 Sep;65(9):1184-7. Epub 2006 Jan 13.

42.

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N.

Arthritis Rheum. 2005 Jul;52(7):1986-92.

43.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N.

Ann Rheum Dis. 2005 Oct;64(10):1414-20. Epub 2005 Apr 20.

44.

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Ann Rheum Dis. 2005 Oct;64(10):1421-6. Epub 2005 Apr 13.

45.

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.

Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L; ARTIS Group.

Ann Rheum Dis. 2005 Feb;64(2):246-52. Epub 2004 Jun 18.

46.
47.

Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.

Baecklund E, Sundström C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L.

Arthritis Rheum. 2003 Jun;48(6):1543-50.

48.

Patients' views of priority setting for new medicines. A qualitative study of patients with rheumatoid arthritis.

Lindblad AK, Hartzema AG, Jansson L, Feltelius N.

Scand J Rheumatol. 2002;31(6):324-9.

PMID:
12492246
49.

[New drugs require nw follow-up surveillance].

Feltelius N, Lindblad S.

Lakartidningen. 2001 Feb 28;98(9):951-3. Swedish.

PMID:
11292975
50.

A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions.

Blomqvist P, Feltelius N, Löfberg R, Ekbom A.

Aliment Pharmacol Ther. 2001 Apr;15(4):475-81.

Supplemental Content

Loading ...
Support Center